Health
Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19 – Loma Linda University Health
ACTIV-2 is studying multiple early COVID-19 treatments
Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19.Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…
Continue Reading